Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035501 | 0.82 | CPB1 (0.57) | PKMNPSR1ALDH1A1MAPT | |
| SCHEMBL18616977 | 0.80 | PKM (0.49) | MEN1KMT2APKMNPSR1LMNA | |
| SCHEMBL6753494 | 0.79 | FUCA1 (0.45) | FUCA1PKMNPSR1ALDH1A1HSD17B10 | |
| SCHEMBL31285384 | 0.77 | SMN1; SMN2 (0.42) | FUCA1MEN1KMT2APKMNPSR1 | |
| SCHEMBL4489378 | 0.76 | CTSB (0.47) | PKMNPSR1ALDH1A1HSD17B10MAPT | |
| SCHEMBL7890595 | 0.76 | CTSB (0.47) | PKMNPSR1ALDH1A1HSD17B10MAPT | |
| SCHEMBL13282255 | 0.76 | CTSB (0.47) | PKMNPSR1ALDH1A1HSD17B10MAPT | |
| SCHEMBL16674651 | 0.75 | CPB1 (0.55) | PKMNPSR1ALDH1A1MAPT | |
| SCHEMBL31368058 | 0.75 | PKM (0.46) | MEN1KMT2APKMNPSR1LMNA | |
| SCHEMBL28315281 | 0.74 | PPID (0.47) | FUCA1MEN1KMT2APKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8614213-B2 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | FUCA1 3808/4885MEN1 1261/4885KMT2A 3893/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | FUCA1 3648/4885MEN1 1219/4885KMT2A 3887/4885 |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | CRHR1, CRH, CRHR2 | FUCA1 3342/4885MEN1 2153/4885KMT2A 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.